A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
PHASE1CompletedINTERVENTIONAL
Enrollment
22
Participants
Timeline
Start Date
Not specified
Study Completion Date
May 31, 1995
Conditions
HIV Infections
Interventions
BIOLOGICAL
gp160 Vaccine (Immuno-AG)
Trial Locations (2)
63104
St. Louis Univ. School of Medicine AVEG, St Louis
98144
UW - Seattle AVEG, Seattle
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00001037 - A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules | Biotech Hunter | Biotech Hunter